Supportive analyses included total hHF events (first plus recurrent) and post-hHF death. Main Outcomes and Measures Prespecified secondary analyses compared the effect on hHF, hHF or CV death, and hHF or all-cause death composite outcomes overall and in prespecified subgroups. Interventions Patients were randomized to sitagliptin vs placebo added to standard care. The study dates were December 2008 through March 2015. Participants included 14 671 patients with T2DM and atherosclerotic vascular disease.

The setting was 673 sites in 38 countries. Objective To assess the association of sitagliptin use with hospitalization for HF (hHF) and related outcomes.ĭesign, Setting, and Participants TECOS was a randomized, double-blind, placebo-controlled study evaluating the CV safety of sitagliptin vs placebo, each added to usual antihyperglycemic therapy and CV care among patients with T2DM and prevalent atherosclerotic vascular disease. The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and secondary composite atherosclerotic cardiovascular (CV) outcomes in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS). Importance Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM).

Shared Decision Making and Communication.

Scientific Discovery and the Future of Medicine.

Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.

To heart 2 dx plus download free